Inpye Pharma Secures RMB 250 Million in Series D++ Financing and Files for Hong Kong IPO

November 15, 2024 - Nanjing Impact Therapeutics Co., Ltd. (hereinafter referred to as “Impact Therapeutics”), an innovative drug R&D company focused on the synthetic lethality mechanism in oncology,We are pleased to announce the successful completion of our RMB 250 million Series D++ financing round, which was jointly invested by globally renowned industrial investment firms and prominent insurance funds. Zhoudou Capital served as the exclusive financial advisor for this round.。

This round of financing will support the commercialization of Senaparib, IMPACT Therapeutics’ core product with best-in-class efficacy, as well as the global clinical development of multiple compounds, including a PARP1-selective inhibitor, while also accelerating the research and development of several early-stage projects.

Dr. Cai Suixiong, CEO of IMPACT Therapeuticsstated: “We are pleased to announce the successful completion of our D++ round financing. We sincerely thank our new investors for their support and trust in IMPACT Therapeutics, and we also extend our gratitude to our existing shareholders for their continued support throughout the company’s development.”

“IMPACT Therapeutics has built a source-innovative synthetic lethality R&D platform after more than ten years of research and development accumulation, and has assembled an R&D operations team with excellent execution capabilities. We look forward to leveraging Huadong Medicine’s extensive marketing network and professional academic promotion experience as our commercialization partner, so that senaparib can benefit more ovarian cancer patients as soon as possible, bringing new and better options for first-line maintenance treatment of ovarian cancer.”

Senaparib (IMP4297) is a novel, highly potent PARP1/2 inhibitor independently developed by IMPACT Therapeutics. Its unique molecular structure ensures excellent target selectivity and a broad safety window. Early clinical trials have demonstrated the promising anti-tumor efficacy of senaparib, including significant therapeutic effects in ovarian cancer. Senaparib met its primary endpoint in the pivotal Phase III registration study (FLAMES). In September 2023, IMPACT Therapeutics announced that the National Medical Products Administration (NMPA) had accepted its New Drug Application (NDA) for senaparib in China. In August 2022, the fixed-dose combination capsule of senaparib and temozolomide (TMZ) for the treatment of adult patients with small cell lung cancer (SCLC) was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). In December 2023, IMPACT Therapeutics entered into a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), for the commercial promotion of senaparib (IMP4297) in mainland China. Huadong Medicine obtained the exclusive marketing rights for senaparib in mainland China.

IMPACT Therapeutics is dedicated to the research and development of innovative, proprietary targeted anticancer drugs, with a focus on synthetic lethality mechanisms. Building on its independently developed products targeting the DNA damage response (DDR) pathway, the company has established one of the most comprehensive DDR pipelines among global biopharmaceutical companies and is progressively expanding into additional novel synthetic lethality targets. The company’s pipeline includes PARP inhibitors (Senaparib/IMP4297), Wee1 inhibitors (IMP7068), ATR inhibitors (IMP9064), selective PARP1 inhibitors (IMP1734, co-developed with Eikon Therapeutics in the United States), and inhibitors targeting several other DDR pathways. Its most advanced candidate, the PARP inhibitor Senaparib (IMP4297), is undergoing Phase II/III clinical trials globally, including in China, for indications such as ovarian cancer and small cell lung cancer. The Phase III clinical trial of Senaparib as first-line maintenance therapy for all-comers with advanced ovarian cancer (FLAMES) has met its primary endpoint, demonstrating best-in-class efficacy and safety. Based on the FLAMES results, the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for Senaparib. Phase I clinical trials of the Wee1 inhibitor IMP7068 and the ATR inhibitor IMP9064 are being conducted in multiple countries and regions worldwide, including the United States and China, and the recommended Phase 2 doses (RP2D) have been determined. The selective PARP1 inhibitor IMP1734 has received Investigational New Drug (IND) clearance from both the U.S. Food and Drug Administration (FDA) and the NMPA, with the first patient enrolled in early 2024.